We showed a significant prevalence in ALK IHC positive NSCLC in HR+ NSCLC compared to HR- NSCLC; this combination has not been studied much in lung cancer and may be worth further investigation first by evaluating HR+ in ALK fusion NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.